Medicus Pharma称FDA对Teverelix优化版二期AUR研究方案给出正面反馈并获IRB批准

Medicus Pharma Receives Positive FDA Feedback For Optimized Phase 2 Study Of Teverelix In AUR
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
Biotech Daily Dose
By
TajSabreen Ahamed
✉
|
Published:
7/16/2026 9:19 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Medicus Pharma Ltd. (
MDCX
) announced that it has reveived written feedback from the FDA and central Institutional Review Board approval for its redesigned Phase 2 clinical study of Teverelix in men following a first episode of acute urinary retention. The regulatory and ethical milestones mark a significant step forward in advancing the company's development program.
Acute urinary retention (AUR) is a serious complication often associated with benign prostatic hyperplasia, causing sudden inability to urinate and requiring immediate medical intervention. Current treatment options remain limited, underscoring the need for novel therapies.
The study, designated ANT-2111-02, is a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the pharmacodynamic effects of Teverelix DP, a long-acting gonadotropin-releasing hormone (GnRH) antagonist, on prostate volume and urinary function. The optimized protocol reduces anticipated enrolment from about 390 patients to approximately 126, making the program more capital-efficient while still generating decision-grade clinical evidence.
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, said: "FDA's positive feedback and central IRB approval represent meaningful progress toward advancing our Teverelix Program. By redesigning this study, we believe we have transformed the development program into a substantially more efficient clinical strategy while preserving our ability to generate robust data."
Medicus emphasized that the streamlined study design is expected to accelerate clinical development, optimize capital allocation, and support future FDA interactions, late-stage trials, and potential strategic partnerships.
MDCX has traded between $0.25 and $3.35 over the past year. The stock closed Wednesday's trading at $0.34, down 4.23%. In pre-market trading the stock is at $0.36, up 5.40%.
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Next Story
Latest Updates on Middle East War
Weakness Among Tech Stocks May Weigh On Wall Street
July 16, 2026 08:55 ET
U.S. Dollar Slides Amid Weaker-Than-Expected PPI Data
July 15, 2026 17:00 ET
Crude Oil Slips Amid EIA Data Release, Trump's Mixed Message To Iran
July 15, 2026 14:41 ET
Canadian Stocks Advance As Investors Parse BoC Monetary Policy Amid U.S.-Iran War
July 15, 2026 16:29 ET
Gold Slides Amid Concerns Of Expansive Gulf War, U.S. PPI Data Release
July 15, 2026 13:41 ET
View More
Global Economics Weekly Update - July 6 – July 10, 2026
July 13, 2026 10:12 ET
The week saw the release of the minutes of the Federal Reserve’s latest monetary policy session, foreign trade figures and survey data on manufacturing and services in the U.S. External trade data from Germany was the highlight in Europe, while the latest macroeconomic projections from the Asian Development Bank and the International Monetary Fund gained attention.
View More Videos
RELATED NEWS
Medicus Pharma Submits FDA Rare Pediatric Designation For SkinJect In Gorlin Syndrome
Medicus Pharma Seeks FDA Rare Pediatric Disease Designation For SkinJect In Gorlin Syndrome
Medicus Pharma Submits IND Application For PRECISION-E2 Endometriosis Trial
Medicus Submits Phase 2b SKNJCT-005 Design For SkinJect In Gorlin Syndrome; Stock Up
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
New Study Shows Updated COVID Vaccine Reduces Severe Illness And Hospitalizations
June 24, 2026 13:12 ET
Editor's Pick
Most Read
Most Emailed
Abbott Q2 Profit Plunges, Lifts FY26 Adj. EPS View, Backs Sales Forecast; Stock Up 11%
July 16, 2026 09:41 ET
Unitedhealth Stock Gains On Strong Q2 Profit, Raised FY26 Outlook
July 16, 2026 07:11 ET
Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down
July 15, 2026 07:51 ET
Goldman Sachs Q2 Net Profit Nearly Doubles; Boosts Dividend 11% - Update
July 14, 2026 08:09 ET
JPMorgan Chase Q2 Profit, AUM Climb; But Shares Drop
July 14, 2026 07:27 ET
Bank Of America Q2 Net Profit Rises - Update
July 14, 2026 07:06 ET
Ericsson Stock Drops On Weak Q2, Cautious View On Q3 Networks Margin
July 14, 2026 06:15 ET
Holtec Nuclear Files For IPO On Nasdaq
July 11, 2026 01:58 ET
First Hawaiian To Acquire TriCo Bancshares In All-Stock Deal; Posts Preliminary Q2
July 13, 2026 07:50 ET
Delivery Hero Confirms Advanced Negotiations With Uber On Potential Acquisition Offer
July 15, 2026 02:05 ET
ABB Agrees To Buy Rotork In Deal With $5.5 Bln Enterprise Value
July 16, 2026 01:21 ET
Barratt Redrow Sees FY26 Adjusted Pre-tax Profit In Line With View; Launches £386 Mln Share Buyback
July 15, 2026 02:52 ET
First Bancorp To Acquire First Carolina In $166 Mln Stock-and-Cash Deal
July 14, 2026 09:28 ET
SGX Posts 31% Rise In June Derivatives Volume
July 13, 2026 01:39 ET
Diodes To Buy ElevATE Semiconductor For $250 Mln In Cash
July 14, 2026 09:13 ET
Citigroup Q2 Profit Climbs On Revenue Strength; But Shares Down - Update
July 14, 2026 08:59 ET
FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer
July 11, 2026 01:21 ET
Apple Sues Former Employees And OpenAI Over Trade Secret Theft
July 11, 2026 03:17 ET
Renault Group Wins High Court Ruling In London Diesel Emissions Case
July 11, 2026 02:23 ET
Kaneko Seeds Co Ltd Full Year Profit Advances
July 13, 2026 01:25 ET
Takeda And Indonesia Announce Plasma Collaboration To Build ASEAN's First Regional Hub
July 12, 2026 21:05 ET
Unifor Reaches Tentative Agreement With Ford For 5,150 Canadian Workers
July 12, 2026 21:55 ET
Gjensidige Q2 Profit From Cont. Ops. Declines
July 13, 2026 02:01 ET
ASIC: Deutsche Bank Pays A$2 Mln Penalty For Systemic Trade Reporting Failures
July 13, 2026 01:15 ET
Astena Holdings Co.,Ltd. Announces Climb In H1 Profit
July 13, 2026 02:14 ET
Amended: Gjensidige Forsikring ASA Q2 Profit Drops
July 13, 2026 01:28 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
.
About Us
Privacy
Sitemap